Straits Times Index
3,309.21 -12.87 (-0.39%) S&P 500
5,338.36 -22.43 (-0.42%) Dow
38,561.61 -306.43 (-0.79%) Nasdaq
17,164.30 -28.23 (-0.16%) Bitcoin USD
66,888.32 -2,514.41 (-3.62%) CMC Crypto 200
1,386.54 -55.09 (-3.82%)
Capricor Therapeutics, Inc. (CAPR)
| Previous close | 5.41 |
| Open | 5.38 |
| Bid | 5.38 x 300 |
| Ask | 5.54 x 300 |
| Day's range | 5.38 - 5.55 |
| 52-week range | 2.68 - 8.22 |
| Volume | |
| Avg. volume | 375,858 |
| Market cap | 174.168M |
| Beta (5Y monthly) | 3.97 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway
--FDA Grants Pre-BLA Meeting Request and Rolling BLA Submission after Review of HOPE-2 and HOPE-2 OLE 3-Year Results-- SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the successful completion of a Type-B meeting with the U.S. Food and Drug Administration (FDA) on next steps for the Biologics License Application (BLA) submiss
- GlobeNewswire
Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
--Results in Performance of the Upper Limb (PUL 2.0) Continue to Show Benefits in Skeletal Muscle Function After 3 Years of CAP-1002 Treatment (p< 0.001)-- --Stabilization in Left Ventricular Ejection Fraction (LVEF) Suggests Preservation of Cardiac Function-- --Results Recently Shared with FDA at Type-B Meeting Held in May 2024-- SAN DIEGO, June 04, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutic
- GlobeNewswire
Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
–Phase 3, HOPE-3 Trial (Cohort A) of CAP-1002 in Duchenne Muscular Dystrophy Fully Enrolled; On Track to Report Top-Line Data in Q4 2024– –Positive Type-B CMC FDA Meeting held in Q1; Company Aligned with FDA on Demonstration of Non-Clinical Comparability, A Major Milestone on Path to CMC Clearance for BLA– –Received First Milestone Payment of $10 Million under U.S. Distribution and Commercialization Agreement with Nippon Shinyaku in Q1– –Recent FDA Feedback Supports Requests for a Pre-BLA Meetin
